Brief: Zai Lab Partner Bristol Myers Squibb Announces Confirmatory Trial For KRAZATI Meets Primary Endpoint
April 1 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB PARTNER BRISTOL MYERS SQUIBB ANNOUNCES PIVOTAL
KRYSTAL-12 CONFIRMATORY TRIAL EVALUATING KRAZATI (ADAGRASIB)
MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL FOR PATIENTS
WITH PRETREATED KRASG12C-MUTATED LOCALLY ADVANCED OR
METASTATIC...
* ZAI LAB LTD: EXPECTS TO SUBMIT NDA FOR ADAGRASIB TO NMPA
FOR
KRAS(G12C) MUTATED NSCLC IN SECOND OR LATER LINE TREATMENT IN
CHINA THIS YEAR.
* ZAI LAB LTD: FDA ASSIGNED A PRESCRIPTION DRUG USER FEE ACT
(PDUFA) GOAL DATE OF JUNE 21, 2024
Source text for Eikon: ID:nBw2vql7Ha
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows